Amubarvimab
Amubarvimab Basic information
- Product Name:
- Amubarvimab
- Synonyms:
-
- Amubarvimab
- Research Grade Amubarvimab (DVV00311)
- Research Grade Amubarvimab
- Amubarvimab (anti-Spike RBD)
- CAS:
- 2509447-07-6
- MW:
- 0
- Mol File:
- Mol File
Amubarvimab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Amubarvimab Usage And Synthesis
Uses
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants[1][2].
in vivo
Amubarvimab (10-50 mg/kg; i.p.) in combination with romlusevimab significantly decreases viral load in the lungs, and reduces lung pathology in a Syrian golden hamster model of SARS-CoV-2 infection[1].
References
[1] Ji Y, et, al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435. DOI:10.3389/fimmu.2022.980435
[2] Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drug. 2022 Aug;82(12):1327-1331. DOI:10.1007/s40265-022-01759-3
AmubarvimabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com